StudyFinder

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Recruiting
I'm interested

This study is NOT accepting healthy volunteers

Estrogen Receptor Positive Breast Cancer, HER-2 Positive Breast Cancer

HER2+, HR+, breast cancer, malignant tumor of the breast, metastatic breast cancer

Lauren Aase - lauren.aase@parknicollet.com
Phase III
201707881
NCT02947685
See this study on ClinicalTrials.gov

Back